scholarly journals New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib

2017 ◽  
Vol Volume 10 ◽  
pp. 2513-2526 ◽  
Author(s):  
Vera Hirsh
Keyword(s):  
Lung Cancer ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Squamous Cell Lung Cancer ◽  
New Developments

scholarly journals Genetically Raised Circulating Bilirubin Levels and Risk of Ten Cancers: A Mendelian Randomization Study

Cells ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 394
Author(s):  
Nazlisadat Seyed Seyed Khoei ◽  
Robert Carreras-Torres ◽  
Neil Murphy ◽  
Marc J. Gunter ◽  
Paul Brennan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Hodgkin’S Lymphoma ◽  
Mendelian Randomization ◽  
Hodgkin's Lymphoma ◽  
Squamous Cell Lung Cancer ◽  
Phenotypic Variance ◽  
A Genome

Bilirubin, an endogenous antioxidant, may play a protective role in cancer development. We applied two-sample Mendelian randomization to investigate whether genetically raised bilirubin levels are causally associated with the risk of ten cancers (pancreas, kidney, endometrium, ovary, breast, prostate, lung, Hodgkin’s lymphoma, melanoma, and neuroblastoma). The number of cases and their matched controls of European descent ranged from 122,977 and 105,974 for breast cancer to 1200 and 6417 for Hodgkin’s lymphoma, respectively. A total of 115 single-nucleotide polymorphisms (SNPs) associated (p < 5 × 10−8) with circulating total bilirubin, extracted from a genome-wide association study in the UK Biobank, were used as instrumental variables. One SNP (rs6431625) in the promoter region of the uridine-diphosphoglucuronate glucuronosyltransferase1A1 (UGT1A1) gene explained 16.9% and the remaining 114 SNPs (non-UGT1A1 SNPs) explained 3.1% of phenotypic variance in circulating bilirubin levels. A one-standarddeviation increment in circulating bilirubin (≈ 4.4 µmol/L), predicted by non-UGT1A1 SNPs, was inversely associated with risk of squamous cell lung cancer and Hodgkin’s lymphoma (odds ratio (OR) 0.85, 95% confidence interval (CI) 0.73–0.99, P 0.04 and OR 0.64, 95% CI 0.42–0.99, p 0.04, respectively), which was confirmed after removing potential pleiotropic SNPs. In contrast, a positive association was observed with the risk of breast cancer after removing potential pleiotropic SNPs (OR 1.12, 95% CI 1.04–1.20, p 0.002). There was little evidence for robust associations with the other seven cancers investigated. Genetically raised bilirubin levels were inversely associated with risk of squamous cell lung cancer as well as Hodgkin’s lymphoma and positively associated with risk of breast cancer. Further studies are required to investigate the utility of bilirubin as a low-cost clinical marker to improve risk prediction for certain cancers.

scholarly journals Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancer

2008 ◽  
Vol 7 (1) ◽  
pp. 62 ◽  
Author(s):  
Paul P Anglim ◽  
Janice S Galler ◽  
Michael N Koss ◽  
Jeffrey A Hagen ◽  
Sally Turla ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Dna Methylation ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Squamous Cell Lung Cancer

scholarly journals Pembrolizumab‐induced pancytopenia in a patient with squamous cell lung cancer

2020 ◽  
Vol 11 (9) ◽  
pp. 2731-2735 ◽  
Author(s):  
Yuriko Ueki ◽  
Manabu Suzuki ◽  
Yuriko Horikawa ◽  
Hiromu Watanabe ◽  
Yoh Yamaguchi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Squamous Cell Lung Cancer
Sign in / Sign up

Export Citation Format

Share Document